# US 2023/0056661 A1 · Methods and compositions for production of xenogeneic islet cells and treatment of insulin-resistant or -deficient conditions with the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0056661 A1
- Document ID: US20230056661A1
- Status: Published application
- Kind: A1
- Application number: 17/790,797
- Filed: 2021-01-07
- Published: 2023-02-23
- Earliest claimed: 2020-01-07
- Applicants: eGenesis, Inc.; Hangzhou Qihan Biotechnology Co., Ltd.
- Inventors: Yangbin GAO; Yanan YUE; Luhan YANG; Marc GUELL; Yinan KAN; Wenning QIN
- Web page: https://patentgrep.com/patent/US20230056661A1

## CPC

- A01K 67/0275: Genetically modified vertebrates, e.g. transgenic
- C12N 5/0676: {Pancreatic cells}
- A01K 67/0273: Cloned vertebrates
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 31/4402: only substituted in position 2, e.g. pheniramine, bisacodyl
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/727: Heparin; Heparan
- A61K 35/39: Pancreas; Islets of Langerhans (Langerhans cells of epidermis A61K35/36)
- A61K 38/28: Insulins
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- C07K 16/2887: {against CD20}
- C12N 5/0677: {Three-dimensional culture, tissue culture or organ culture; Encapsulated cells}
- A01K 2207/15: Humanized animals
- A01K 2217/052: inducing gain of function
- A01K 2217/075: inducing loss of function, i.e. knock out
- A01K 2217/15: Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
- A01K 2227/108: Swine
- A01K 2267/025: Animal producing cells or organs for transplantation
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C12N 2501/999: Small molecules not provided for elsewhere
- C12N 2509/00: Methods for the dissociation of cells, e.g. specific use of enzymes
- C12N 2509/10: Mechanical dissociation
- C12N 2510/00: Genetically modified cells
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Described here are methods, compositions, and systems for generating transgenic islet cells suitable for xenotransplantation.

## Claims

### Claim 1

An isolated transgenic porcine islet cell, wherein said cell:
(a) is substantially free of enzymatic activity of at least one glycosyltransferase enzyme, wherein said glycosyltransferase enzyme is GGTA, B4GALNT2, or CMAH;
(b) expresses at least two polypeptide sequences derived from a non-porcine mammalian species, wherein said at least two polypeptide sequences comprise at least two of CD46, CD55, CD59, THBD, TFPI, CD39, B2M, HLAE, CD47, A20, PD-L1, FASL, or HO-1; and
(c) exhibits one or more of the following: reduced toxicity from complement derived from said non-porcine mammalian species, reduced induction of activated protein C coagulation derived from said non-porcine mammalian species, reduced induction of thrombin-antithrombin complex derived from said non-porcine mammalian species, or reduced toxicity from NK cells derived from said non-porcine species.

### Claim 2 (depends on 1)

The transgenic porcine islet cell of claim 1, wherein said cell is substantially free of enzymatic activity of at least two, or all three glycosyltransferase enzymes selected from GGTA, B4GALNT2, and CMAH.

### Claim 3 (depends on 1, 2)

The transgenic porcine islet cell of claim 1 or 2, wherein said cell expresses at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, or all of: CD46, CD55, CD59, THBD, TFPI, CD39, B2M, HLAE, CD47, A20, PD-L1, FASL, or HO-1.

### Claim 4

An isolated transgenic porcine islet cell, wherein said islet cell:
(a) is substantially free of enzymatic activity of at least two glycosyltransferase enzymes, wherein said glycosyltransferase enzymes comprise at least two of GGTA, B4GALNT2, or CMAH;
(b) expresses a polypeptide sequence derived from a non-porcine mammalian species, wherein said polypeptide sequence is CD46, CD55, CD59, THBD, TFPI, CD39, B2M, HLAE, CD47, A20, PD-L1, FASL, or HO-1; and
(c) exhibits reduced toxicity from complement derived from said non-porcine mammalian species, reduced induction of activated protein C coagulation derived from said non-porcine species, reduced induction of thrombin-antithrombin complex derived from said non-porcine species, or reduced toxicity from NK T-cells derived from said non-porcine species.

### Claim 5 (depends on 4)

The transgenic porcine islet cell of claim 4, wherein said cell is substantially free of enzymatic activity of GGTA, B4GALNT2, and CMAH.

### Claim 6 (depends on 4, 5)

The transgenic porcine islet cell of claim 4 or 5, wherein said cell expresses at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, or all of CD46, CD55, CD59, THBD, TFPI, CD39, B2M, HLAE, CD47, A20, PD-L1, FASL, or HO-1.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The transgenic porcine islet cell of any one of claims 1-6, expressing CD46, CD55, CD59, CD39, B2M, HLAE, and CD47.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

The transgenic porcine islet cell of any one of claims 1-6, wherein said cell is substantially free of expression of said glycosyltransferase enzyme or enzymes.

### Claim 9 (depends on 8)

The transgenic porcine islet cell of claim 8, wherein said cell comprises a frameshift mutation in said glycosyltransferase enzyme or enzymes resulting in premature termination of translation, thereby ablating activity of said glycosyltransferase enzyme.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The transgenic porcine islet cell of any one of claims 1-9, wherein a nucleic acid sequence or sequences encoding said polypeptide sequence or sequences derived from non-porcine mammalian species are inserted within non-orthologous loci of the porcine ortholog.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The transgenic porcine islet cell of any one of claims 1-10, wherein a nucleic acid sequence or sequences encoding said polypeptide sequence or sequences derived from non-porcine mammalian species are operably linked to non-orthologous promoters of the porcine ortholog.

### Claim 12 (depends on 11)

The transgenic porcine islet cell of claim 11, wherein said non-orthologous promoters are non-porcine promoters.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The transgenic porcine islet cell of any one of claims 1-12, wherein said islet cell is derived by disaggregation of a porcine pancreas.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The transgenic porcine islet cell of any one of claims 1-13, wherein said islet cell is an alpha cell, a beta cell, a delta cell, an epsilon cell, a Pancreatic polypeptide (PP) cell, or any combination thereof.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The transgenic porcine islet cell of any one of claims 1-14, wherein said non-porcine mammalian species is a primate species.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The transgenic porcine islet cell of any one of claims 1-15, wherein said cell exhibits survival greater than 8 days when transplanted into said non-porcine mammalian species.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The transgenic porcine cell of any one of claims 1-16, wherein said cell exhibits a reduced IBMIR to PBMCs isolated from said non-porcine mammalian species.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

A composition comprising a therapeutically effective amount of isolated porcine islet cells according to any one of claims 1-17.

### Claim 19 (depends on 18)

The composition of claim 18, wherein said isotonic buffered solution further comprises heparin or a TNF-alpha inhibitor.

### Claim 20 (depends on 18, 19)

The composition of claim 18 or 19, comprising at least about 12% to about 25% beta cells or at least about 15% to about 30% alpha cells.

### Claim 21 (depends on 18, 19, 20, 35, 36, 37, 38, 39, 40, 41, 42)

The composition of any one of claims 18-20, wherein said composition is prepared according to any one of claims 35-42.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

A method of treating an insulin resistant or deficient condition in a non-porcine mammal in need thereof, comprising administering a therapeutically effective dose of isolated transgenic porcine islet cells according to any one of claims 1-17 or a composition according to any one of claims 18-21 to said mammal.

### Claim 23 (depends on 22)

The method of claim 22, comprising centrally administering said cells via an internal jugular vein or a hepatic portal vein of said mammal.

### Claim 24 (depends on 22, 23)

The method of any one of claims 22-23, wherein said insulin resistant condition comprises type 1 diabetes mellitus.

### Claim 25 (depends on 22, 23)

The method of any one of claims 22-23, wherein said insulin resistant condition comprises type 2 diabetes mellitus.

### Claim 26 (depends on 22, 23, 24, 25)

The method of any one of claims 22-25, wherein said non-porcine mammal has received an induction regimen comprising therapeutically effective doses of anti-thymocyte globulin, anti-CD40 antibody, anti-CD20 antibody, a rapalog, a calcineurin inhibitor, ganciclovir or a prodrug thereof, an antihistamine, and a corticosteroid prior to administering said transgenic porcine islet cell or said composition.

### Claim 27 (depends on 22, 23, 24, 25, 26)

The method of any one of claims 22-26, comprising administering therapeutically effective doses of anti-CD40 antibody, a rapalog, a calcineurin inhibitor, and ganciclovir or a prodrug thereof following administration of said transgenic porcine islet cell or said composition.

### Claim 28 (depends on 22, 23, 24, 25, 26, 27)

The method of any one of claims 22-27, comprising administering therapeutically effective doses of an intermediate- or long-acting insulin analog, insulin glargine, insulin detemir, or NPH insulin following administration of said transgenic porcine islet cell or said composition.

### Claim 29 (depends on 22, 23, 24, 25, 26, 27, 28)

The method of any one of claims 22-28, wherein said therapeutically effective dose is at least 5,000 IEQ per kg of non-porcine mammal body weight.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

An isolated porcine islet comprising an isolated porcine islet cell according to any one of claims 1-17.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

An isolated porcine pancreatic organoid comprising an isolated porcine islet cell according to any one of claims 1-17.

### Claim 32 (depends on 30, 31)

The isolated porcine islet or isolated porcine pancreatic organoid of claim 30 or 31, wherein said islet or organoid is substantially free of pancreatic exocrine cells.

### Claim 33 (depends on 31, 32)

The isolated porcine pancreatic organoid of claim 31 or 32; wherein said pancreatic organoid is prepared by:
(a) isolating a pancreas from a neonatal porcine animal on neonatal day 7 or earlier; and
(b) subjecting said pancreas to mechanical or enzymatic digestion to generate organoid fragments, and optionally:
(c) purifying organoid fragments of step (b) by ficoll gradient sedimentation.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

An isolated porcine pancreas comprising a porcine islet cell according to any one of claims 1-17.

### Claim 35

A method of improving yield of islets from a porcine donor prior to transplantation to a non-porcine mammalian recipient, comprising
(a) providing pancreatic organoids from a neonatal porcine animal that have been subjected to a purification procedure;
(b) culturing said organoids in the presence of an effective concentration of a caspase inhibitor for at least 90 minutes following said purification; and
(c) continuing culture in the presence of an effective concentration of a corticosteroid for at least 7 days.

### Claim 36 (depends on 35)

The method of claim 35; wherein said purification procedure comprises:
(a) isolating a pancreas from a transgenic neonatal porcine animal on neonatal day 7 or earlier; and
(b) subjecting said pancreas to mechanical or enzymatic digestion to generate organoid fragments, and optionally:
(c) purifying organoid fragments from said digested pancreas by ficoll gradient sedimentation.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 35, 36)

The method of claim 35 or 36, wherein said neonatal porcine animal is a transgenic pig comprising at least one porcine cell according to any one of claims 1-17.

### Claim 38 (depends on 35, 36, 37)

The method of any one of claims 35-37, wherein said caspase inhibitor is Z-VAD-FMK.

### Claim 39 (depends on 35, 36, 37, 38)

The method of any one of claims 35-38, wherein said corticosteroid is methylprednisolone.

### Claim 40 (depends on 35, 36, 37, 38, 39)

The method of any one of claims 35-39, wherein said pancreatic organoids are cultured in the presence of IBMX, a phosphodiesterase inhibitor, or an adenosine receptor antagonist.

### Claim 41 (depends on 35, 36, 37, 38, 39, 40)

The method of any one of claims 35-40, wherein said pancreatic organoids are cultured in the presence of nicotinamide or a metabolically acceptable analog thereof.

### Claim 42 (depends on 35, 36, 37, 38, 39, 40, 41)

A method of treating an insulin resistant or deficient condition in a non-porcine mammal in need thereof, comprising transplanting organoids according to any one of claims 35-41 into said non-porcine mammalian mammal when said organoids meet any of the following criteria (a) endotoxin less than about 5 EU/kg;
(b) negative gram stain;
(c) viability greater than about 70%; or
(d) islet concentration greater than or equal to about 20,000 IEQ/mL of total settled volume.
